Schistosoma mansoni: assessment of morbidity before and after control

Lambertucci, J R; Serufo, José Carlos; Gerspacher-Lara, Rogério; Rayes, Abdunnabi Ahmed Mustafa; Teixeira, Rosângela; Nobre, Vandack; Antunes, Carlos

doi:10.1016/s0001-706x(00)00124-8

Cited by 141 publications

(97 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The most important fi ndings are echogenic thickening of the walls of the portal vein and its branches, indicative of periportal fi brosis, and echogenic enlargement of the gallbladder wall. However, US is a subjective procedure and is therefore examiner-dependent [23][24][25][26][27][28][29][30][31][32] .…”

Section: Ultrasound In Hepatosplenic Schistosomiasismentioning

confidence: 99%

“…In endemic areas, at least four groups of individuals have been identifi ed using the data obtained by abdominal palpation and US examination: 1) a spleen >13cm and liver periportal fi brosis, as confi rmed by US; 2) a palpable spleen and spleen >13cm, as measured by US; 3) a spleen >13cm using US and 4) a palpable spleen 15,30 .…”

Section: Ultrasound In Hepatosplenic Schistosomiasismentioning

confidence: 99%

See 1 more Smart Citation

Revisiting the concept of hepatosplenic schistosomiasis and its challenges using traditional and new tools

Lambertucci

2014

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

Different aspects of hepatosplenic schistosomiasis are revisited here. Manson's schistosomiasis causes periportal fi brosis and portal hypertension in approximately 6% of infected subjects, usually with preservation of their hepatic function. The assessment of liver involvement is of major importance in determining the prognosis and risk of complications from schistosomiasis, such as upper digestive bleeding secondary to variceal rupture. For many years, the diagnosis of hepatosplenic schistosomiasis and liver fi brosis was made by abdominal palpation and the fi nding of liver and/or spleen enlargement. However, there is no consensus regarding the clinical parameters of the liver and spleen to be considered in this physical evaluation. For the last three decades, abdominal ultrasound (US) has become the best imaging technique to evaluate liver fi brosis caused by schistosomiasis mansoni. However, US is a subjective procedure and is therefore examiner-dependent. Magnetic resonance imaging (MRI) fi ndings have provided valuable information in addition to ultrasound and clinical examination. The combination of a comprehensive history and physical examination, basic laboratory tests (a stool examination for Schistosoma mansoni eggs and a blood cell count), biomarkers for liver fi brosis/portal hypertension and imaging methods seem to offer the best approach for evaluating patients with this disease. In situations where research is involved or in patients with severe disease, MRI may be considered.

show abstract

Section: Ultrasound In Hepatosplenic Schistosomiasismentioning

confidence: 99%

Section: Ultrasound In Hepatosplenic Schistosomiasismentioning

confidence: 99%

Revisiting the concept of hepatosplenic schistosomiasis and its challenges using traditional and new tools

Lambertucci

2014

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

show abstract

“…In Figure 1, [21][22][23][24] . All patients had three negative parasitological stool examinations by the Kato-Katz technique and they also reported previous treatment for schistosomiasis ranging from 2 to 5 years before being enrolled in the present investigation.…”

Section: Patientsmentioning

confidence: 99%

“…Since then, over 13 million treatments/ re-treatments were undertaken in the country 4,[18][19][20][21][22] .…”

Section: Introductionmentioning

confidence: 99%

Glomerulonephritis in schistosomiasis mansoni: a time to reappraise

Rodrigues

Otoni

Voieta

et al. 2010

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

Introduction:The current prevalence of glomerulonephritis in patients with hepatosplenic schistosomiasis mansoni in Brazil was evaluated. Methods: Sixty three patients (mean age 45.5±11 years) attending the outpatient infectious disease clinic of a University Hospital in Belo Horizonte, Brazil, from 2007 to 2009, were consecutively examined and enrolled in the present investigation. Diagnosis of hepatosplenic schistosomiasis was based on epidemiological, clinical and parasitological data and imaging techniques. Eight patients, who presented >30mg/day albuminuria, were submitted to percutaneous ultrasound guided renal biopsy. Kidney tissue fragments were examined under light, direct immunofluorescence and electron microscopy. Results: All patients showed mesangial enlargement. In five, mesangial hypercellularity was observed and four presented duplication of the glomerular basement membrane. Areas of glomerular sclerosis were diagnosed in four. Deposits of immunoglobulin M and C3 were present in six samples; deposits of IgG in four, IgA in three and C1q in two samples. In all patients, immunoglobulin A was reported in the lumen of renal tubules. Deposits of kappa and lambda were observed in six samples. Electron microscopy revealed dense deposits in the glomerular tissue of three patients. Arterial hypertension, small esophageal varices, slight increases in serum creatinine and decreases in serum albumin were associated with glomerular disease. Conclusions: Renal disease associated with hepatosplenic schistosomiasis was verified in 12.7% of patients and type I membranoproliferative glomerulonephritis was observed in 50% of them. Schistosomal glomerulopathy still is an important problem in patients with hepatosplenic schistosomiasis in Brazil.

show abstract

“…Since control of schistosomiasis in high burden areas is primarily concerned with morbidity reduction through the use of regular anthelminthic chemotherapy (Fenwick et al, 2003;Utzinger and Keiser, 2004;WHO, 2002WHO, , 2004, interest has increased in better describing the public health burdens of schistosomiasis both at national and local levels (van der Werf et al, 2002(van der Werf et al, , 2003, as well as clearly demonstrating morbidity reversion post treatment (Boisier et al, 1998;Brooker et al, 2004;Lambertucci et al, 2000).…”

Section: Introductionmentioning

confidence: 99%